LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Elenco Azioni・Organon & Co

Search

Organon & Co

Chiusa

SettoreSettore sanitario

13.4 -0.22

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.39

Massimo

13.43

Metriche Chiave
By Trading Economics
Entrata	351M 146M
Vendite	-47M 1.5B
P/E Media del settore	14.441 50.102
EPS	0.71
Rendimento da dividendi	0.6
Margine di Profitto	10
Dipendenti	10,000
EBITDA	286M 351M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	-8.19% downside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	0.60% 2.33%
Utili prossimi	4 ago 2026
Prossima data del Dividendo	11 giu 2026
Prossima data del' Ex Dividendo	14 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	71M 3.5B
Apertura precedente	13.62
Chiusura precedente	13.4

Notizie sul Sentiment di mercato

By Acuity

74%

26%

306 / 344 Classifica in Healthcare

Organon & Co Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 apr 2026, 06:09 UTC

Acquisizioni, Fusioni, Takeovers

India's Sun Pharma to Buy U.S. Healthcare Company Organon in $11.75 Billion Deal -- 2nd Update

27 apr 2026, 02:33 UTC

Acquisizioni, Fusioni, Takeovers

India's Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal - Update

27 apr 2026, 01:04 UTC

Acquisizioni, Fusioni, Takeovers

Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion

7 nov 2025, 14:41 UTC

Acquisizioni, Fusioni, Takeovers

Laborie to Buy Specialist Medical Device For Up To $465 Million From Organon

27 apr 2026, 18:07 UTC

Acquisizioni, Fusioni, Takeovers

Organon Rides the Pharma M&A Wave With Sun Takeover. The Stock Sizzles. -- Barrons.com

27 apr 2026, 15:14 UTC

Acquisizioni, Fusioni, Takeovers

Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal -- Update

27 apr 2026, 14:56 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

27 apr 2026, 13:58 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

27 apr 2026, 13:38 UTC

Azioni calde

Stocks to Watch Monday: Frontier, Domino's Pizza, Qualcomm -- WSJ

27 apr 2026, 12:18 UTC

Acquisizioni, Fusioni, Takeovers

Another Pharma Takeover Shows the Sector Is Hot. Organon Stock Rides the M&A Wave. -- Barrons.com

27 apr 2026, 09:22 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Jumps After Sun Seals Takeover. Why Pharma M&A Is a Hot Play. -- Barrons.com

27 apr 2026, 00:38 UTC

Acquisizioni, Fusioni, Takeovers

Sun Pharmaceutical to Acquire Organon Shares for $14.00 Each in an All Cash Deal

27 apr 2026, 00:38 UTC

Acquisizioni, Fusioni, Takeovers

Sun Pharmaceutical to Acquire Organon & Co. at an Enterprise Value of $11.75B

24 apr 2026, 20:51 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 19:25 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 17:09 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

10 apr 2026, 20:10 UTC

Acquisizioni, Fusioni, Takeovers

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 apr 2026, 14:39 UTC

Acquisizioni, Fusioni, Takeovers

Update: This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 apr 2026, 14:01 UTC

Acquisizioni, Fusioni, Takeovers

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 apr 2026, 09:23 UTC

Azioni calde

Stocks to Watch Friday: Lumentum, Coherent, Porsche -- WSJ

Confronto tra pari

Modifica del prezzo

Organon & Co Previsione

Obiettivo di Prezzo

By TipRanks

-8.19% in calo

Previsioni per 12 mesi

Media 12.33 USD -8.19%

Alto 14 USD

Basso 9 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Organon & Co - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

4 ratings

0

Acquista

4

Mantieni

0

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Organon & Co - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

306 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Altri titoli del settore

LLY

Eli Lilly and Co.

1,066.57

JNJ

Johnson and Johnson

230.23

ABBV

AbbVie Inc

212.63

UNH

UnitedHealth Group Inc

377.52

AZN

AstraZeneca PLC

187.14

Live chat